Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 2

3(33.3%)

Phase 3

2(22.2%)

9Total

Phase 1(4)

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03315364Phase 2Active Not Recruiting

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Role: lead

NCT06318845Phase 1Completed

Phase 1 Study of DHP2302R1 and DHP2302R2 in Healthy Adult Volunteers

Role: lead

NCT01839773Phase 3Completed

Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer

Role: lead

NCT06395155Phase 1Completed

A Phase 1 Clinical Trial DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers

Role: lead

NCT04675528Phase 1Completed

Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study

Role: lead

NCT03326102Phase 2Completed

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

Role: lead

NCT05503953Phase 3Unknown

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Role: collaborator

NCT03055741Phase 2Completed

Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)

Role: lead

NCT02890511Phase 1Completed

A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer

Role: lead

All 9 trials loaded